贝卡林的无形固体分散及其对性结肠炎的口腔治疗作用
Yaxin Jia1, Jiajia Gengji1, Tao Gong1
1Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Pharmaceutical research
|December 12, 2024
概括
一种新型的氨酸-氨酸复合物 (BA-Arg) 改善了性结肠炎 (UC) 治疗的口服吸收和抗炎作用. 这种环保配方增强了贝卡林.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物运输 药物运输 药物运输
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 治疗受到副作用,长时间和高成本的挑战.
- 贝卡林 (BA) 对炎症性肠病具有抗炎潜力,但具有较差的溶解性和生物可用性.
- 解决这些局限性对于开发有效的基于BA的UC疗法至关重要.
研究的目的:
- 为了克服贝卡林 (BA) 的水溶性差和口服生物可用性降低.
- 开发一种创新的治疗方法来治疗性结肠炎 (UC),使用BA.
- 创建一个贝卡林-阿尔金因复合体 (BA-Arg) 来增强药物输送.
主要方法:
- 通过冷干燥方法开发了贝卡林-氨酸复合物 (BA-Arg).
- 选了合适的基本化合物,以形成BA-Arg复合体.
- 在BA-Arg复合体内产生了BA的无形固体分散.
主要成果:
- BA-Arg显著增强了BA的肠道吸收和跨膜传输,而不会对Caco-2细胞产生毒性.
- 在老鼠中的药理动力学研究显示,与自由BA相比,BA-Arg的血BA度更高.
- 在小鼠模型中,BA-Arg治疗显著缓解了结肠炎症状,减少了炎症并保护了肠道粘膜.
结论:
- 该研究提出了一种简单,环保的配方工艺,以提高BA的溶解性.
- BA-Arg综合体为基于BA的UC疗法提供了一种实用和可持续的解决方案.
- 这种方法提高了baicalin的抗结肠炎疗效.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:21Drugs for Treatment of Constipation-Predominant IBS
134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
01:29Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142